Patents by Inventor Keon-Wook Kang

Keon-Wook Kang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240148836
    Abstract: In a method for treating a cancer expressing secreted protein acidic and rich in cysteine (SPARC), a composition including an albumin and at least one cysteine bound thereto is administered to a subject in need thereof. The cancer expressing the SPARC may be at least one selected from the group consisting of a brain tumor, melanoma, breast cancer, rectal cancer and stomach cancer.
    Type: Application
    Filed: August 14, 2023
    Publication date: May 9, 2024
    Inventors: Keon Wook KANG, Myung Geun SONG, Cho Rong PARK, Yun-Sang LEE, Hye Won YOUN, Ji Yong PARK, Se Ra OH
  • Patent number: 11793772
    Abstract: Provided is a composition comprising 2,4,6-trihydroxyacetophenone (THA) as an active ingredient, and a method for preventing, alleviating or treating breast cancer using the composition by inhibiting the activity of polo-like kinase 1 (PlK1).
    Type: Grant
    Filed: October 19, 2017
    Date of Patent: October 24, 2023
    Assignee: KOREA UNITED PHARM. INC.
    Inventors: Keon Wook Kang, Kwang-Seok Oh, Youngchul Kim, Sung Baek Jeong
  • Patent number: 11484511
    Abstract: The present invention relates to a composition comprising 2,4,6-trihydroxyacetophenone (THA) as an effective ingredient for prevention or treatment of prostate cancer. THA in the present invention is a main ingredient of Curcuma comosa. The composition of the present invention effectively inhibits the growth of prostate cancer by regulating in particular the activity of polo-like kinase 1 (PLK1) and thus is expected to find useful applications in use in the prevention, alleviation, and treatment of prostate cancer in future.
    Type: Grant
    Filed: December 26, 2018
    Date of Patent: November 1, 2022
    Assignee: KOREA UNITED PHARM, INC.
    Inventors: Keon Wook Kang, Sung Baek Jeong
  • Publication number: 20220339263
    Abstract: A composition for treatment of a cancer according to an embodiment of the present disclosure expresses secreted protein acidic and rich in cysteine (SPARC). The composition includes an albumin and at least one cysteine bound thereto.
    Type: Application
    Filed: February 22, 2022
    Publication date: October 27, 2022
    Inventors: Keon Wook KANG, Myung Geun SONG, Cho Rong PARK, Yun-Sang LEE, Hye Won YOUN, Ji Yong PARK, Se Ra OH
  • Publication number: 20210338759
    Abstract: The present invention relates to a pharmaceutical composition for prevention or treatment of an allergic disease comprising a mixed extract of two or more selected from the group consisting of Asiasarum root, Platycodon root, and Cinnamomi ramulus as an active ingredient; a method for prevention or treatment of an allergic disease using the pharmaceutical composition; and a health functional food and a feed composition for improvement of an allergic disease. The composition provided in the present invention comprising a mixed extract of two or more selected from the group consisting of Asiasarum root, Platycodon root, and Cinnamomi ramulus as an active ingredient can specifically inhibit the differentiation of Th2 cells and thus can be effectively used as a composition for prevention or treatment of an allergic disease.
    Type: Application
    Filed: May 28, 2019
    Publication date: November 4, 2021
    Inventors: Hyun Ok YANG, Keon Wook KANG, Sung Won KWON, Jeong Hill PARK, Hocheol KIM, Myung Sook OH, Dae Sik JANG, Doheon LEE, Hak Cheol KWON, Byung Hwa JUNG
  • Publication number: 20210093583
    Abstract: The present invention relates to a composition comprising 2,4,6-trihydroxyacetophenone (THA) as an effective ingredient for prevention or treatment of prostate cancer. THA in the present invention is a main ingredient of Curcuma comosa. The composition of the present invention effectively inhibits the growth of prostate cancer by regulating in particular the activity of polo-like kinase 1 (PLK1) and thus is expected to find useful applications in use in the prevention, alleviation, and treatment of prostate cancer in future.
    Type: Application
    Filed: December 26, 2018
    Publication date: April 1, 2021
    Applicant: KOREA UNITED PHARM. INC.
    Inventors: Keon Wook KANG, Sung Baek JEONG
  • Patent number: 10639320
    Abstract: The present invention relates to a pharmaceutical composition for preventing or treating liver fibrosis or liver cirrhosis, and more specifically, to a pharmaceutical composition for preventing or treating liver fibrosis or liver cirrhosis comprising a gold-containing agent. The pharmaceutical composition of the present invention, by comprising the gold-containing agent as an active ingredient, not only promotes M2-type transformation of macrophages but also inhibits the activation of stellate cells due to the increase of TREM-2 expression, and is thus expected to be effectively used as a pharmaceutical composition, a food composition, etc., for preventing, treating, or ameliorating liver fibrosis or liver cirrhosis. Additionally, gold-containing agents, such as auranofin, sodium aurothiomalate, and aurothioglucose, have long been used for the treatment of a different disease (rheumatoid arthritis), and thus they have an advantage in that they are less likely to cause adverse effects.
    Type: Grant
    Filed: August 20, 2015
    Date of Patent: May 5, 2020
    Assignee: KOREA UNITED PHARM. INC.
    Inventors: Keon Wook Kang, Nayoun Kim, Kyung Rok Yoon
  • Publication number: 20190262281
    Abstract: Provided is a composition comprising 2,4,6-trihydroxyacetophenone (THA) as an active ingredient, and a method for preventing, alleviating or treating breast cancer using the composition by inhibiting the activity of polo-like kinase 1 (PLK1).
    Type: Application
    Filed: October 19, 2017
    Publication date: August 29, 2019
    Applicant: KOREA UNITED PHARM. INC.
    Inventors: Keon Wook KANG, Kwang-Seok OH, Youngchul KIM, Sung Baek JEONG
  • Publication number: 20190008864
    Abstract: The present invention relates to a pharmaceutical composition containing a G protein coupled receptor 119 (GPR119) ligand as an effective ingredient for preventing or treating non-alcoholic steatohepatitis. More particularly, it was confirmed that the GPR119 ligand, which has been developed as only an anti-diabetic drug, exhibits superior effects on the treatment of non-alcoholic fatty liver and the signal pathways in hepatocytes therefor differ from the signal pathways in the small intestine and the pancreas exhibiting anti-diabetic effects, whereby the GPR119 ligand can be useful to treat non-alcoholic steatohepatitis.
    Type: Application
    Filed: July 19, 2018
    Publication date: January 10, 2019
    Applicant: PHARMEDIX.CO., LTD.
    Inventors: Keon Wook KANG, Kyeong LEE, Jin Won YANG
  • Patent number: 9895370
    Abstract: Provided is a pharmaceutical composition for preventing or treating liver fibrosis, comprising a GPR119 ligand as an active ingredient. The composition comprising the GPR119 ligand as an active ingredient significantly inhibits the expression of collagen I, transforming growth factor ? (TGF?) and ?-smooth muscle actin (?-SMA), thereby inhibiting HSC activation, and also significantly inhibits HSC proliferation. Therefore, the composition may be effectively applied in improvement, prevention, inhibition or treatment of liver fibrosis.
    Type: Grant
    Filed: November 18, 2016
    Date of Patent: February 20, 2018
    Assignee: PHARMEDIX.CO., LTD
    Inventors: Keon Wook Kang, Kyeong Lee, Jin Won Yang
  • Patent number: 9833145
    Abstract: Provided are a method for simultaneously detecting fluorescence and Raman signals for multiple fluorescence and Raman signal targets, and a medical imaging device for simultaneously detecting multiple targets using the method. The method includes: injecting at least one marker particle comprising Raman markers and receptors into the body of an animal, which can be a human; irradiating a laser beam onto the body of the animal; and detecting the optical signals emitted by the marker particle after the irradiation of the laser beam separately as fluorescence signals and Raman signals. The simultaneous detection of multiple targets may be performed even without scanning optical signals emitted by the marker particle individually with different optical fibers. As an examination may be performed by injecting surface-enhanced Raman marker particles, weak Raman signals may be augmented so as to obtain a more accurate diagnosis result in real time.
    Type: Grant
    Filed: January 4, 2017
    Date of Patent: December 5, 2017
    Assignee: SNU R&DB FOUNDATION
    Inventors: Dae Hong Jeong, Keon Wook Kang, Dong Soo Lee, Yoon Sik Lee, Gun Sung Kim, Bong Hyun Jun, Jin Chul Paeng, Ho Young Lee, Yun Sang Lee
  • Publication number: 20170266219
    Abstract: The present invention relates to a pharmaceutical composition for preventing or treating liver fibrosis or liver cirrhosis, and more specifically, to a pharmaceutical composition for preventing or treating liver fibrosis or liver cirrhosis comprising a gold-containing agent. The pharmaceutical composition of the present invention, by comprising the gold-containing agent as an active ingredient, not only promotes M2-type transformation of macrophages but also inhibits the activation of stellate cells due to the increase of TREM-2 expression, and is thus expected to be effectively used as a pharmaceutical composition, a food composition, etc., for preventing, treating, or ameliorating liver fibrosis or liver cirrhosis. Additionally, gold-containing agents, such as auranofin, sodium aurothiomalate, and aurothioglucose, have long been used for the treatment of a different disease (rheumatoid arthritis), and thus they have an advantage in that they are less likely to cause adverse effects.
    Type: Application
    Filed: August 20, 2015
    Publication date: September 21, 2017
    Applicant: KOREA UNITED PHARM. INC.
    Inventors: Keon Wook Kang, Nayoun Kim, Kyung Rok Yoon
  • Publication number: 20170143714
    Abstract: Provided is a pharmaceutical composition for preventing or treating liver fibrosis, comprising a GPR119 ligand as an active ingredient. The composition comprising the GPR119 ligand as an active ingredient significantly inhibits the expression of collagen I, transforming growth factor ? (TGF?) and ?-smooth muscle actin (?-SMA), thereby inhibiting HSC activation, and also significantly inhibits HSC proliferation.
    Type: Application
    Filed: November 18, 2016
    Publication date: May 25, 2017
    Applicants: DONGGUK UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION, SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION
    Inventors: Keon Wook KANG, Kyeong LEE, Jin Won YANG
  • Publication number: 20170112380
    Abstract: Provided are a method for simultaneously detecting fluorescence and Raman signals for multiple fluorescence and Raman signal targets, and a medical imaging device for simultaneously detecting multiple targets using the method. The method includes: injecting at least one marker particle comprising Raman markers and receptors into the body of an animal, which can be a human; irradiating a laser beam onto the body of the animal; and detecting the optical signals emitted by the marker particle after the irradiation of the laser beam separately as fluorescence signals and Raman signals. The simultaneous detection of multiple targets may be performed even without scanning optical signals emitted by the marker particle individually with different optical fibers. As an examination may be performed by injecting surface-enhanced Raman marker particles, weak Raman signals may be augmented so as to obtain a more accurate diagnosis result in real time.
    Type: Application
    Filed: January 4, 2017
    Publication date: April 27, 2017
    Inventors: Dae Hong JEONG, Keon Wook KANG, Dong Soo LEE, Yoon Sik LEE, Gun Sung KIM, Bong Hyun JUN, Jin Chul PAENG, Ho Young LEE, Yun Sang LEE
  • Publication number: 20170049773
    Abstract: The present invention relates to a pharmaceutical composition containing a G protein coupled receptor 119 (GPR119) ligand as an active ingredient for preventing or treating non-alcoholic fatty liver disease. More particularly, it was confirmed that the GPR119 ligand, which has been developed as only an anti-diabetic drug, exhibits superior effects on the treatment of non-alcoholic fatty liver and the signal pathways in hepatocytes therefor differ from the signal pathways in the small intestine and the pancreas exhibiting anti-diabetic effects, whereby the GPR119 ligand can be useful to treat non-alcoholic fatty liver.
    Type: Application
    Filed: January 23, 2015
    Publication date: February 23, 2017
    Applicants: DONGGUK UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION, SNU R&DB FOUNDATION
    Inventors: Keon Wook KANG, Kyeong LEE, Jin Won YANG
  • Publication number: 20130137944
    Abstract: Method pertains to a medical imaging device for simultaneously detecting fluorescence and Raman signals for multiple fluorescence and Raman signal targets. The method includes: injecting at least one marker particle including Raman markers and receptors into the body of an animal, which can be a human; irradiating a laser beam onto the body of the animal; and detecting the optical signals emitted by the marker particle after the irradiation of the laser beam separately as fluorescence signals and Raman signals. The simultaneous detection of multiple targets may be performed even without scanning optical signals emitted by the marker particle individually with different optical fibers. As an examination may be performed by injecting surface-enhanced Raman marker particles, into which fluorescent components are introduced, into the body of the animal using a spray or the like, weak Raman signals may be augmented so as to obtain a more accurate diagnosis result in real time.
    Type: Application
    Filed: August 11, 2011
    Publication date: May 30, 2013
    Applicant: SNU R&DB FOUNDATION
    Inventors: Dae Hong Jeong, Keon Wook Kang, Dong Soo Lee, Yoon Sik Lee, Gun Sung Kim, Bong Hyun Jun, Jin Chul Paeng, Ho Young Lee, Yun Sang Lee
  • Publication number: 20100316635
    Abstract: A kit and a composition comprising Herceptin, an antibody binding specifically to HER2, based on detecting Herceptin-sensitive HER2-overexpressing cells are provided for diagnosing cancer. A method of detecting Herceptin-sensitive HER2-overexpressing cells using the same is also provided.
    Type: Application
    Filed: October 16, 2008
    Publication date: December 16, 2010
    Applicant: NATIONAL CANCER CENTER
    Inventors: Eun Sook Lee, Keon Wook Kang, Byong Chul Yoo, Ho-Young Lee, Sun Young Kong, Se Hun Kang, Nam Suk Baek, Bu-Mi Kwon, Young Mi Kwon
  • Patent number: 7078045
    Abstract: A pharmaceutical composition for treatment and prevention of liver fibrosis and cirrhosis, which comprises 5-(2-pyrazinyl)-4-methyl-1,2-dithiol-3-thione (oltipraz) and dimethyl-4,4?-dimethoxy-5,6,5?,6?-dimethylene dioxybiphenyl-2,2?-dicarboxylate (DDB) as major components, is provided. The ratio of oltipraz and DDB of said composition is preferably 25:0–25, more preferably 5:0.1–5, particularly preferably 5:1. Oltipraz/DDB formulations according to the present invention exhibit surprisingly good effect on the treatment and prevention of liver fibrosis and cirrhosis and are safe drugs that have low toxicity in the human body.
    Type: Grant
    Filed: March 2, 2001
    Date of Patent: July 18, 2006
    Assignee: Sang-Geon Kim
    Inventors: Sang-Geon Kim, Keon-Wook Kang
  • Publication number: 20060063781
    Abstract: The present invention provides a pharmaceutical composition and the use thereof for regeneration of liver tissues to treat cirrhotic liver, the composition including 5-(2-pyrazinyl)-4-methyl-1,2-dithiol-3-thione (oltipraz) as an active ingredient. The oltipraz composition promotes regeneration of liver tissues in a cirrhotic liver, thereby useful in treating cirrhosis.
    Type: Application
    Filed: October 28, 2005
    Publication date: March 23, 2006
    Inventors: Sang-Geon Kim, Keon-Wook Kang, Yoon-Gyoon Kim, Min-Kyung Cho
  • Publication number: 20030171382
    Abstract: The present invention provides a pharmaceutical composition and the use thereof for regeneration of liver tissues to treat cirrhotic liver, the composition including 5-(2-pyrazinyl)-4-methyl-1,2-dithiol-3-thione (oltipraz) as an active ingredient. The oltipraz composition promotes regeneration of liver tissues in a cirrhotic liver, thereby useful in treating cirrhosis.
    Type: Application
    Filed: February 6, 2003
    Publication date: September 11, 2003
    Inventors: Sang-Geon Kim, Keon-Wook Kang, Yoon-Gyoon Kim, Min-Kyung Cho